Molbio Diagnostics targets consumables-led growth as Truenat utilisation expands globally

Investment View and Truenat Platform

Motilal Oswal Financial Services initiated coverage of Molbio Diagnostics in its October 2026 report with a BUY rating. The broker views the company as well positioned in decentralised molecular diagnostics through its proprietary Truenat ecosystem. The thesis is built on a device-led installed base that generates recurring, higher-value test-kit consumption, an expanding assay menu, international scale-up and operating leverage.

Molbio’s portable, battery-operated PCR platform provides point-of-care molecular testing with an approximately 60-minute turnaround time and limited infrastructure requirements. This makes it relevant for primary health centres, remote locations and smaller healthcare facilities.

Truenat was Molbio’s principal growth engine, contributing about 90 per cent of FY26 revenue. The platform had more than 12,500 devices across over 90 countries, 43 assays covering 30 diseases and deployments at 8,000–9,000 diagnostic centres.

The broker highlights the shift from one-time device sales to recurring consumables. Truenat device and test-kit sales delivered respective 18 per cent and 84 per cent CAGRs over FY23–26. TB kits accounted for 74 per cent of consumables revenue in FY26. Broader use of existing devices through non-TB assays, including HPV, is expected to increase utilisation.

Partnerships for sepsis and meningitis panels, TB triage and treatment monitoring, breast-cancer screening, veterinary assays and other point-of-care products are intended to expand the addressable assay menu.

Financial Performance and Operating Trends

Reported consolidated sales rose at a 31 per cent CAGR during FY24–26 to Rs14.5 billion in FY26. Truenat test kits accounted for 72 per cent of FY26 consolidated revenue and grew 41.6 per cent year on year, while devices represented 14 per cent of revenue and were broadly flat.

In Q1 FY27, test-kit volumes reached 6.2 million units. The period also benefited from Rs570 million of export orders deferred from Q4 FY26 because of Gulf-related disruptions. The broker notes that TB represented 96 per cent of test-kit volumes in FY26, underscoring the platform’s continuing dependence on TB testing.

Growth Outlook and Capacity Utilisation

Motilal Oswal estimates a 23 per cent revenue CAGR for FY26–29E, with sales rising from Rs14.5 billion to Rs26.8 billion. It expects EBITDA and adjusted PAT to grow at 38 per cent and 50 per cent CAGRs respectively, reaching Rs8.4 billion and Rs5.7 billion by FY29E.

EBITDA margin is forecast to rise from 22.2 per cent in FY26 to 31.3 per cent in FY29E, while PAT margin is projected to reach 21.1 per cent. Existing plant utilisation of about 58 per cent for kits and 42 per cent for devices is considered sufficient for roughly two times revenue growth without significant new spending.

The broker expects return on equity to recover from 15.8 per cent in FY26 to about 26 per cent in FY29E as margins and the interest burden improve.

Adjacency Opportunities

Prognosys

Prognosys complements the point-of-care strategy through ultra-portable X-ray imaging and ProRad TB screening, which can create incremental Truenat testing. Motilal Oswal expects Prognosys revenue to grow at a 36 per cent CAGR to Rs3.9 billion by FY29E.

OptraSCAN

OptraSCAN provides digital pathology exposure through whole-slide scanners, cloud infrastructure and AI-enabled analysis. Its July 2026 USFDA 510(k) clearance is an important gateway for US commercialisation, although the segment was still at an early stage and made a negligible FY26 revenue contribution. The broker forecasts OptraSCAN revenue of about Rs2.9 billion by FY29E.

Valuation and Target Price

The broker values Molbio at 45 times 12-month forward earnings, a 20 per cent premium to the sector multiple of 36 times. This reflects the company’s differentiated R&D-led model and earnings-growth potential. The valuation produces a target price of Rs1,800.

Key Risks

• Customer concentration and dependence on government procurement and tender cycles.
• High exposure to TB testing.
• Working-capital intensity.
• Slower-than-expected Truenat adoption or test-kit commercialisation.
• Regulatory or product-registration delays.
• Reduced TB funding.
• Competitive or technological pressure from global diagnostics players.